Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous disorder characterized by personality changes, language impairment, and deficits of executive functions associated with frontal and temporal lobe degeneration. Different phenotypes have been defined on the basis of presenting clinical symptoms, i.e., the behavioral variant of FTD, the agrammatic variant of primary progressive aphasia, and the semantic variant of PPA. Some patients have an associated movement disorder, either parkinsonism, as in progressive supranuclear palsy and corticobasal syndrome, or motor neuron disease (FTD-MND). A family history of dementia is found in 40% of cases of FTD and about 10% have a clear autosomal-dominant inheritance. Genetic studies have identified several genes associated with monogenic FTD: microtubule-associated protein tau, progranulin, TAR DNA-binding protein 43, valosin-containing protein, charged multivesicular body protein 2B, fused in sarcoma, and the hexanucleotide repeat expansion in intron 1 of the chromosome 9 open reading frame 72. Patients often present with an extensive phenotypic variability, even among different members of the same kindred carrying an identical disease mutation. The objective of the present work is to review and evaluate available literature data in order to highlight recent advances in clinical, biological, and neuroimaging features of monogenic frontotemporal lobar degeneration and try to identify different mechanisms underlying the extreme phenotypic heterogeneity that characterizes this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 7×
“, 2006), and subsequently renamed FTLD-TDP (Arai et al., 2006; Neumann et al., 2006).”
InfluentialSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 7×
“Two different protein isoforms of the C9orf72 gene are predicted to be generated from a total of three different transcripts variants, depending on the localization of the GGGGCC repeat, either in the promoter or in the intron 1 of the gene (DeJesus-Hernandez et al., 2011).”
BackgroundInfluentialA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409 · cited 2×
“…evaluated the frequency of heterozygous TREM2 mutations as risk factor in FTD patients, confirming that the Q33X, R47H, and T66M mutations were significantly associated with the disease and absent in healthy subjects (Borroni et al., 2013), in line with further reports (Cuyvers et al., 2013).”
BackgroundResultAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · cited 3×
“Genetic studies have identified several genes associated with monogenic FTD: in 1998, mutations in the microtubule-associated protein tau (MAPT) gene on chromosome 17 were identified in families with FTD and parkinsonism (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“…TREM2 exon 2 mutations were identified in rare families presenting with autosomal recessive bvFTD without any clinical or radiological evidence of bone involvement (Giraldo et al., 2013; Guerreiro, 2013; Guerreiro et al., 2013a; Lattante et al., 2013; Rayaprolu et al., 2013; Le Ber et al., 2014).”
BackgroundArai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 3×
“So far, mutations in the TARDBP gene account for 2–3% of ALS patients (Gitcho et al., 2008; Kabashi et al., 2008; Kühnlein et al., 2008; Rutherford et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008; Daoud et al., 2009).”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · cited 16×
“One study identified a missense mutation in a patient with FTD-ALS (p.S120Y) and in a single case of limb onset sporadic ALS (p.T182M) (Schymick et al., 2006), while a later study identified clinical features compatible with MND in 5.4% of patients carrying a GRN mutation; in this September 2015 | Volume 7 | Article 1…”
BackgroundInfluentialSelf-citationTARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544 · cited 3×
“So far, mutations in the TARDBP gene account for 2–3% of ALS patients (Gitcho et al., 2008; Kabashi et al., 2008; Kühnlein et al., 2008; Rutherford et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008; Daoud et al., 2009).”
BackgroundCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 3×
“The initially reported and most common clinical diagnosis in patients carrying GRN mutations is bvFTD, with significant apathy and social withdrawal (Baker et al., 2006; Cruts et al., 2006).”
BackgroundMutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 2×
“Genetic studies have identified several genes associated with monogenic FTD: in 1998, mutations in the microtubule-associated protein tau (MAPT) gene on chromosome 17 were identified in families with FTD and parkinsonism (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).”
BackgroundWatts, G. D. J., Wymer, J., Kovach, M. J., Mehta, S. G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M. P., & Kimonis, V. E. (2004) · Nature Genetics · doi:10.1038/ng1332 · Cited by 1,391 · cited 6×
“Moreover, nearly 60% patients develop adult-onset Paget disease of bone (Watts et al., 2004).”
BackgroundInfluentialTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S.-C., Sun, E., Wancewicz, E., Mazur, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2779 · Cited by 1,335
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS
Johnson, J. O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V. M., Trojanowski, J. Q., Gibbs, J. R., Brunetti, M., Gronka, S., Wuu, J., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.036 · Cited by 1,235
Majounie, E., Renton, A. E., Mok, K., Dopper, E. G., Waite, A., Rollinson, S., Chiò, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70043-1 · Cited by 1,210
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration
Lagier-Tourenne, C., Polymenidou, M., & Cleveland, D. W. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq137 · Cited by 1,021
Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · cited 1×
“Abnormal intracellular accumulation of insoluble proteins have been identified with immunohistochemical techniques and, according to the predominant neuronal inclusions, FTLD cases have been categorized into several types (Mackenzie et al., 2008, 2010).”
BackgroundGoedert, M., & Jakes, R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07870.x · Cited by 929 · cited 2×
“org microtubule-binding domains of tau, with 4R tau having greater predisposition for microtubule assembly than 3R tau (Goedert and Jakes, 1990).”
BackgroundRNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
Skibinski, G., Parkinson, N. J., Brown, J. M., Chakrabarti, L., Lloyd, S. L., Hummerich, H., Nielsen, J. E., Hodges, J. R., Spillantini, M. G., Thusgaard, T., et al. (2005) · Nature Genetics · doi:10.1038/ng1609 · Cited by 822 · cited 3×
“2, encodes the charged multivesicular body protein 2B, which has been identified in 2005 in a large Danish family with an autosomal form of FTLD (Skibinski et al., 2005), first described in 1987 (Gydesen et al., 1987).”
BackgroundInfluentialVan Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, L. B., Clay, D., Wood, E. M., Chen-Plotkin, A. S., Martinez-Lage, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70071-1 · Cited by 723
Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683
<emph type="ital">SQSTM1</emph> Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Fecto, F. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.250 · Cited by 650
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609 · cited 1×
“The mean disease duration is 9 years, ranging from 5 to 20 years (Seelaar et al., 2011).”
Background[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Rohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationThe heritability and genetics of frontotemporal lobar degeneration
Rohrer, J. D., Guerreiro, R., Vandrovcova, J., Uphill, J., Reiman, D., Beck, J., Isaacs, A. M., Authier, A., Ferrari, R., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bf997a · Cited by 536
Snowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L., Richardson, A. M. T., Jones, M., Gerhard, A., Davidson, Y. S., Robinson, A., et al. (2012) · Brain · doi:10.1093/brain/awr355 · Cited by 523
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · cited 1×
“, 2013), will undoubtedly improve our future understanding of the pathogenesis of disorders characterized by tau deposition (Villemagne et al., 2015).”
BackgroundStrikingly Different Clinicopathological Phenotypes Determined by Progranulin-Mutation Dosage
Smith, K. R., Damiano, J., Franceschetti, S., Carpenter, S., Canafoglia, L., Morbin, M., Rossi, G., Pareyson, D., Mole, S. E., Staropoli, J. F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.04.021 · Cited by 489 · cited 1×
“September 2015 | Volume 7 | Article 1711 Review published: 01 September 2015 doi: 10.3389/fnagi.2015.00171 Frontiers in Aging Neuroscience | www.frontiersin.org Edited by: Diego Albani, IRCCS Mario Negri Institute for Pharmacological Research, Italy Reviewed by: Federica Agosta,”
BackgroundInfluentialAl-Sarraj, S., King, A., Troakes, C., Smith, B., Maekawa, S., Bodi, I., Rogelj, B., Al-Chalabi, A., Hortobágyi, T., & Shaw, C. E. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0911-2 · Cited by 475
Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)
Parkinson, N., Ince, P. G., Smith, M. O., Highley, R., Skibinski, G., Andersen, P. M., Morrison, K. E., Pall, H. S., Hardiman, O., Collinge, J., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000231510.89311.8b · Cited by 395
Guerreiro, R. J., Lohmann, E., Brás, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.579 · Cited by 374
TDP ‐ 43 mutation in familial amyotrophic lateral sclerosis
Yokoseki, A., Shiga, A., Tan, C., Tagawa, A., Kaneko, H., Koyama, A., Eguchi, H., Tsujino, A., Ikeuchi, T., Kakita, A., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21392 · Cited by 373 · cited 1×
“So far, mutations in the TARDBP gene account for 2–3% of ALS patients (Gitcho et al., 2008; Kabashi et al., 2008; Kühnlein et al., 2008; Rutherford et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008; Daoud et al., 2009).”
BackgroundRNA targets of wild-type and mutant FET family proteins
Hoell, J. I., Larsson, E., Runge, S., Nusbaum, J. D., Duggimpudi, S., Farazi, T. A., Hafner, M., Borkhardt, A., Sander, C., & Tuschl, T. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2163 · Cited by 350
Beck, J., Poulter, M., Hensman, D., Rohrer, J. D., Mahoney, C. J., Adamson, G., Campbell, T., Uphill, J., Borg, A., Fratta, P., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.01.011 · Cited by 345 · cited 1×
“The number of repeat units of the C9orf72 expansion in affected patients can range from at least several hundred to thousands of copies, whereas unaffected healthy controls harbor 2–24 repeat units (DeJesus-Hernandez et al., 2011; Beck et al., 2013; van Blitterswijk et al., 2013).”
BackgroundDipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations
Mackenzie, I. R., Arzberger, T., Kremmer, E., Troost, D., Lorenzl, S., Mori, K., Weng, S.-M., Haass, C., Kretzschmar, H. A., Edbauer, D., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1181-y · Cited by 345 · cited 2×
“Moreover, the recent observation, in a Belgian C9orf72 carrier, of neuropathological aggregates of a DPR core surrounded by TDP-43 inclusions, suggested that DPR aggregation due to RAN translation could be the initial pathological event that possibly precedes and potentially triggers TDP-43 accumulation (Mackenzie et…”
BackgroundProgressive Supranuclear Palsy: Pathology and Genetics
Dickson, D. W., Rademakers, R., & Hutton, M. L. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00054.x · Cited by 314 · cited 5×
“However, some patients have a primary parkinsonian syndrome as in CBS or, more rarely, as in PSP (Dickson et al., 2007; Van Swieten and Spillantini, 2007).”
BackgroundInfluentialSQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Rubino, E., Rainero, I., Chiò, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e25df · Cited by 286
Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)
Cox, L. E., Ferraiuolo, L., Goodall, E. F., Heath, P. R., Higginbottom, A., Mortiboys, H., Hollinger, H. C., Hartley, J. A., Brockington, A., Burness, C. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009872 · Cited by 262
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers
Finch, N., Carrasquillo, M. M., Baker, M., Rutherford, N. J., Coppola, G., DeJesus-Hernandez, M., Crook, R., Hunter, T., Ghidoni, R., Benussi, L., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0e3b · Cited by 243 · cited 1×
“, 2010), a gene encoding for the still uncharacterized transmembrane protein 106B, seem to delay the onset of disease in GRN mutation carriers, perhaps increasing the levels of progranulin (Cruchaga et al., 2011; Finch et al., 2011; van der Zee et al., 2011).”
BackgroundVoxel-based morphometry in autopsy proven PSP and CBD
Josephs, K. A., Whitwell, J. L., Dickson, D. W., Boeve, B. F., Knopman, D. S., Petersen, R. C., Parisi, J. E., & Jack, C. R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.019 · Cited by 234 · cited 1×
“Numerous attempts have been made to identify an in vivo biomarker that can accurately predict the underlying neuropathology and consequently point out which gene should be analyzed, but a clear-cut association between clinical or neuroradiological features and characteristic histological inclusions has not been yet es…”
BackgroundHereditary Frontotemporal Dementia Caused by Tau Gene Mutations
Van Swieten, J., & Spillantini, M. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00052.x · Cited by 195
Yu, C.-E., Bird, T. D., Bekris, L. M., Montine, T. J., Leverenz, J. B., Steinbart, E., Galloway, N. M., Feldman, H., Woltjer, R., Miller, C. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.328 · Cited by 190 · cited 5×
“Nevertheless, behavioral changes with features of psychosis, including hallucinations and delusions, are not rarely observed in these patients (Arighi et al., 2012; Boeve et al., 2012; DobsonStone et al., 2012; Englund et al., 2012; Mahoney et al., 2012; Snowden et al., 2012; Galimberti et al., 2013; Kertesz et al., 2…”
BackgroundInfluentialC9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD
Liu, E. Y., Russ, J., Wu, K., Neal, D., Suh, E., McNally, A. G., Irwin, D. J., Van Deerlin, V. M., & Lee, E. B. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1286-y · Cited by 180
Heterozygous TREM2 mutations in frontotemporal dementia
Borroni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., Fenoglio, C., Piaceri, I., Archetti, S., Bonvicini, C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.017 · Cited by 173 · cited 2×
“…2014), colony-stimulating factor 1 receptor (CFS1R) (Münch et al., 2005; Guerreiro et al., 2013b), triggering receptor expressed on myeloid cells (TREM2) (Borroni et al., 2013; Guerreiro, 2013), ubiquilin-2 (UBQLN2) (Gellera et al., 2013), and heterogeneous nuclear ribonucleoprotein A2B1…”
ResultSelf-citationFrequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia
Poorkaj, P., Grossman, M., Steinbart, E., Payami, H., Sadovnick, A., Nochlin, D., Tabira, T., Trojanowski, J. Q., Borson, S., Galasko, D., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.383 · Cited by 171 · cited 2×
“The frequency of MAPT gene mutations is highly variable, ranging from 0–3% in sporadic FTD to 5–20% in familial cases (Houlden et al., 1999; Rizzu et al., 1999; Poorkaj et al., 2001; Binetti et al., 2003; Rademakers et al., 2004; Kaivorinne et al., 2008; Pickering-Brown et al., 2008).”
BackgroundInfluentialFrontotemporal Dementia Associated With the C9ORF72 Mutation: A Unique Clinical Profile
Devenney, E., Hornberger, M., Irish, M., Mioshi, E., Burrell, J., Tan, R., Kiernan, M. C., & Hodges, J. R. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6002 · Cited by 167
Guerreiro, R., Bilgic, B., Guven, G., Brás, J., Rohrer, J., Lohmann, E., Hanagasi, H., Gurvit, H., & Emre, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.005 · Cited by 158 · cited 1×
“…TREM2 exon 2 mutations were identified in rare families presenting with autosomal recessive bvFTD without any clinical or radiological evidence of bone involvement (Giraldo et al., 2013; Guerreiro, 2013; Guerreiro et al., 2013a; Lattante et al., 2013; Rayaprolu et al., 2013; Le Ber et al., 2014).”
BackgroundStructural and functional brain connectivity in presymptomatic familial frontotemporal dementia
Dopper, E. G. P., Rombouts, S. A. R. B., Jiskoot, L. C., den Heijer, T., de Graaf, J. R. A., de Koning, I., Hammerschlag, A. R., Seelaar, H., Seeley, W. W., Veer, I. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000583 · Cited by 152
Giraldo, M., Lopera, F., Siniard, A. L., Corneveaux, J. J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.016 · Cited by 147
Troakes, C., Maekawa, S., Wijesekera, L., Rogelj, B., Siklós, L., Bell, C., Smith, B., Newhouse, S., Vance, C., Johnson, L., et al. (2012) · Neuropathology · doi:10.1111/j.1440-1789.2011.01286.x · Cited by 124
Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration
Chen-Plotkin, A. S., Martinez-Lage, M., Sleiman, P. M. A., Hu, W., Greene, R., Wood, E. M., Bing, S., Grossman, M., Schellenberg, G. D., Hatanpaa, K. J., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.53 · Cited by 120 · cited 1×
“The clinical presentation in patients with GRN mutations is highly variable, and phenotypic heterogeneity can be observed in the same family carrying an identical pathogenic mutation (Beck et al., 2008; Gabryelewicz et al., 2010; Yu et al., 2010; Chen-Plotkin et al., 2011), with an age-dependent and incomplete penetra…”
BackgroundReduced CSF p-Tau 181 to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113
C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease
Harms, M., Benitez, B. A., Cairns, N., Cooper, B., Cooper, P., Mayo, K., Carrell, D., Faber, K., Williamson, J., Bird, T., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.537 · Cited by 102 · cited 1×
“As in GRN and MAPT mutations, deficits in episodic memory at onset, mimicking AD have been reported also in patients with C9orf72 mutations (Wojtas et al., 2012; Cacace et al., 2013; Harms et al., 2013; Murray et al., 2013; Pletnikova et al., 2014).”
BackgroundPhosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis
Grossman, M., Elman, L., McCluskey, L., McMillan, C. T., Boller, A., Powers, J., Rascovsky, K., Hu, W., Shaw, L., Irwin, D. J., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6064 · Cited by 94 · cited 1×
“Furthermore, the recently identified cerebrospinal phosphotau181 to total-tau ratio appears to predict FTLD-TDP pathology with high accuracy, thus leading to the search of genes associated with TDP-43 neuropathology (Hu et al., 2013; Grossman et al., 2014; Borroni et al., 2015a).”
BackgroundCharacteristics of frontotemporal dementia patients with a Progranulin mutation
Huey, E. D., Grafman, J., Wassermann, E. M., Pietrini, P., Tierney, M. C., Ghetti, B., Spina, S., Baker, M., Hutton, M., Elder, J. W., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20969 · Cited by 87 · cited 1×
“Neuroimaging studies have highlighted that patients carrying a GRN mutation are more likely to show a pronounced asymmetrical atrophy (Huey et al., 2006; Bronner et al., 2007; Beck et al., 2008; Pickering-Brown et al., 2008) affecting either the left or right hemispheres, involving primarily the…”
BackgroundPearson, J. P., Williams, N. M., Majounie, E., Waite, A., Stott, J., Newsway, V., Murray, A., Hernandez, D., Guerreiro, R., Singleton, A. B., et al. (2011) · Journal of Neurology · doi:10.1007/s00415-010-5815-x · Cited by 84 · cited 1×
“Until 2011, despite numerous efforts, the disease mutation remained elusive (Momeni et al., 2006; Morita et al., 2006; Valdmanis et al., 2007; Luty et al., 2008; Le Ber et al., 2009; Boxer et al., 2011; Pearson et al., 2011).”
BackgroundFUS and TDP43 genetic variability in FTD and CBS
Huey, E. D., Ferrari, R., Moreno, J. H., Jensen, C., Morris, C. M., Potocnik, F., Kalaria, R. N., Tierney, M., Wassermann, E. M., Hardy, J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.004 · Cited by 82
Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia
Borroni, B., Benussi, A., Archetti, S., Galimberti, D., Parnetti, L., Nacmias, B., Sorbi, S., Scarpini, E., & Padovani, A. (2015) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.971812 · Cited by 77
Self-citationC9orf72 G4C2 repeat expansions in Alzheimer's disease and mild cognitive impairment
Cacace, R., Van Cauwenberghe, C., Bettens, K., Gijselinck, I., van der Zee, J., Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Bäumer, V., Dillen, L., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.019 · Cited by 74
The C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia
Galimberti, D., Reif, A., Dell'Osso, B., Kittel-Schneider, S., Leonhard, C., Herr, A., Palazzo, C., Villa, C., Fenoglio, C., Serpente, M., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.004 · Cited by 66
Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis
Chen, Y., Li, S., Su, L., Sheng, J., Lv, W., Chen, G., & Xu, Z. (2015) · Journal of Neurology · doi:10.1007/s00415-014-7630-2 · Cited by 50 · cited 1×
“A recent meta-analysis studied the association between the GRN polymorphism rs5848 and risk of neurodegenerative diseases, including FTLD, AD, Parkinson’s disease (PD), and ALS, concluding that rs5848 was associated with an increased risk of AD and PD in the homozygous and recessive models but not with FTLD (Chen et a…”
BackgroundC9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder
Galimberti, D., Reif, A., Dell'Osso, B., Palazzo, C., Villa, C., Fenoglio, C., Kittel‐Schneider, S., Leonhard, C., Olmes, D. G., Serpente, M., et al. (2014) · Bipolar Disorders · doi:10.1111/bdi.12169 · Cited by 36
Ghetti, B., Spina, S., Murrell, J. R., Huey, E. D., Pietrini, P., Sweeney, B., Wassermann, E. M., Keohane, C., Farlow, M. R., & Grafman, J. (2008) · Neurodegenerative Diseases · doi:10.1159/000113706 · Cited by 28 · cited 2×
“, 2008) affecting either the left or right hemispheres, involving primarily the inferior frontal (Bronner et al., 2007; Beck et al., 2008; Ghetti et al., 2008), temporal and inferior parietal lobes (Mesulam et al.”
Background
Cited by
Kovacs, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020189 · Cited by 321
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
Bowles, K. R., Silva, M. C., Whitney, K., Bertucci, T., Berlind, J. E., Lai, J. D., Garza, J. C., Boles, N. C., Mahali, S., Strang, K. H., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.003 · Cited by 182
Genetics of FTLD : overview and what else we can expect from genetic studies
Pottier, C., Ravenscroft, T. A., Sanchez‐Contreras, M., & Rademakers, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13622 · Cited by 148
Frontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 145
Metadata
- Authors
- Benussi, A., Padovani, A., & Borroni, B.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-09-01
- Volume
- 7
- Pages
- 171-171
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2113141773
- Cited by
- 123
- References
- 76
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.